Singer, Susanne; Bayer, Oliver; Schranz, Melanie et al.
"Patient-reported outcomes" in medizinischen Registern: Erfahrungen aus einer Anwendungsbegleitenden DatenerhebungONKOLOGIE. Bd. 30. H. 4. 2024 S. 304-311
Luebke, Johannes; Christen, Deborah; Schwaab, Juliana et al.
Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registriesLEUKEMIA. 2024
Zoeller, Daniela; Haverkamp, Christian; Makoudjou, Adeline et al.
Alpha-1-antitrypsin-deficiency is associated with lower cardiovascular risk: an approach based on federated learningRESPIRATORY RESEARCH. Bd. 25. H. 1. 2024
Kroeger, Nicolaus; Wulf, Gerald; Hegenbart, Ute et al.
Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients under 60 years of age: a prospective, phase II studyHAEMATOLOGICA. Bd. 109. H. 5. 2024 S. 1469-1479
Winter, Susann; Goetze, Katharina S.; Hecker, Judith S. et al.
Clonal hematopoiesis and its impact on the aging osteo-hematopoietic nicheLEUKEMIA. 2024
Salwender, Hans; Weinhold, Niels; Benner, Axel et al.
Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trialHEMATOLOGY. Bd. 29. H. 1. 2024
Al Hariri, Mohammad; Munder, Markus; Pfeiffer, Norbert et al.
Does Systemic Hematological Therapy Influence the Course of Paraproteinemic Keratopathy?JOURNAL OF CLINICAL MEDICINE. Bd. 13. H. 2. 2024
Schetelig, Johannes; Baldauf, Henning; Heidenreich, Falk et al.
Donor <i>KIR</i> genotype based outcome prediction after allogeneic stem cell transplantation: no land in sightFRONTIERS IN IMMUNOLOGY. Bd. 15. 2024
Beelen, Dietrich Wilhelm; Iacobelli, Simona; Koster, Linda et al.
Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients - A clinical trial to registry data comparisonBONE MARROW TRANSPLANTATION. 2024
Leypoldt, Lisa B.; Tichy, Diana; Besemer, Britta et al.
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple MyelomaJOURNAL OF CLINICAL ONCOLOGY. Bd. 42. H. 1. 2024 S. 26-+